Disease never rests.
So neither do we.

Discover how we drive innovation in research and development of preventive adjuvant products to optimize patient health, which is at the heart of everything we do.

Cellular Renovation Therapy is a therapeutic method in complementary medicine that exerts an adjuvant and mainly preventive action by providing fundamental nutrients for cell life, through the use of opotherapeutic embryonic actives, peptides, phyto-organic compounds, enzymes, and powerful antioxidants to neutralize the action of free radicals. It also combats other substances that are part of its exclusive non-chemical formulas that stimulate cell revitalization and regeneration by strengthening the nucleus of the cell and its cycles implementing specific functions within the renewal stage, and subsequent mitosis. The combination of 100% compatible components was included to merge the traditional formulas of organotherapy and cell therapy maximizing the effects of products purely opotherapeutic in origin. The fundamental objective is to revitalize healthy and / or damaged organs, optimizing the function of the tissues affected by possible structural changes.

Cellular Renovation Therapy (CRT) is a form of complementary medicine that focuses on disease prevention and supports the effectiveness of conventional medicine. CRT nourishes cells using natural ingredients, such as animal embryonic extracts, peptides, and antioxidants, which neutralize free radicals and other harmful substances. By strengthening the cell nucleus, enhancing cellular repair, and promoting the natural regeneration process, CRT aims to rejuvenate both healthy and impaired cells, thus optimizing tissue and organ function. This method combines traditional organotherapy with modern cell therapy for maximal therapeutic effects.

Cellular Renovation Therapy Activity in Cells?

CRT aims to rejuvenate aging or diseased organs by providing essential elements like proteins, amino acids, biopeptides, enzymes, and other biochemical substrates and nutrients to foster cellular regeneration, especially in cells deficient in these elements. This process revitalizes various organs and glands, enhancing their functional capacity and overall health.

This process is called the CELLULAR RENOVATION stage. Its beneficial action unfolds gradually because it starts at the cellular level and progresses to tissues, organs, and, ultimately, organ systems. The health transformation is typically observed over several weeks. Several specialists have affirmed that the key outcome of CRT is the rejuvenation of the immune system's defense mechanisms.

Biocell Ultravital is a Swiss brand with over 80 years in the field of developing Cell Renewal Therapies with unique formulations that combine cellular extracts with natural compounds. Their innovative approach is designed to correct cellular dysfunction, the root of most diseases, by addressing imbalances and environmental factors that degrade cell health. For instance, environmental exposure to chemicals and unhealthy lifestyles put a burden on cellular health, resulting in poor nutrient synthesis and toxin elimination. Therefore, Biocell Ultravital treatments leverage on important peptides and enzymes (e.g., glutathione transferase and peroxidase) to remove mutagenic toxins, enhance immune responses, and inhibit cancer cell growth.

The goal of CRT is not to treat the disease’s symptoms in particular but to restore the internal balance of cells through the supply of compounds that enhance cell nutrition, stabilize the cell cycle, and foster regenerative actions. These cellular actions support the body’s overall health and resistance to diseases, particularly degenerative ones.

Moreover, animal organ hydrolysates are rich in multifunctional bioactive peptides, which exhibit numerous health-promoting effects, such as antitumor, antioxidant, antimicrobial, antithrombotic, immunomodulatory, and antihypertensive activities.

Recognizing the therapeutic significance of these bioactive peptides, Biocell Ultravital has integrated them into our 4th generation product formulas. These peptides are extracted from specific organs through meticulous enzymatic hydrolysis. The additional extraction of peptides from organ glands further enhances the beneficial effects in improving organ health and normalizing bodily functions for improved cellular performance. These peptides form a crucial part of our 4th generation therapeutic approaches, marking a new era in the Biocell Ultravital product line.

Contemporary medical views consider the thymus gland as the “brain” of the immune system, integral to the development and function of T-lymphocytes. However, the thymus gland shrinks with age, a process whose causes remain elusive. This process reduces the number of functional T-lymphocytes, weakening the body's defense mechanisms and increasing vulnerability to illnesses as one ages.

In fact, most diseases are linked to immune system dysfunction in some way or another. Therefore, utilizing thymus peptides, enzymes, and other bioactive factors can aid in normalizing immune responses, thereby mitigating these diseases.

From 1953 until his death in 1989, SANDBERG regularly treated his patients with aqueous thymus extract (THX).

From 1964, Dr. Elis Sandberg (1910-1989) frequently used aqueous thymus extract (THX) to treat chronic diseases and cancer across thousands of patients with notable success. As a result, this method reached widespread acclaim in Germany, especially following clinical research showing that THX and thymus peptides significantly improve immunological functions. Patients with chronic and recurrent infections have greatly benefited from THX therapy. Most patients also exhibited noticeable overall health improvements with THX therapy that rejuvenates the immune system.

Thymus peptides are crucial for the activation and differentiation of immature T-cell precursors into mature T-cells. Therefore, the inclusion of thymus gland extracts, thymic peptides, enzymes, and other bioactive components into our Biocell Ultravital's 4th Generation product formulas is essential for enhancing immune system function.

Many illnesses can be traced directly or indirectly to a disorder of the immune system.

The use of peptides, thymus extracts, enzymes, and other components in the formulas of all Biocell Ultravital 4th Generation products provide an important regulator of the immune system mechanism.

In more recent years, the therapeutic use of immunomodulatory thymus peptides has become particularly relevant in three main areas: cancerous tumors (e.g., lung, breast, and prostate cancer), chronic infections, and autoimmune and inflammatory disorders.

Regarding cancer, affected patients typically have primary or secondary immunodeficiency. Primary immunodeficiency refers to inborn genetic errors in immunity. In contrast, secondary immunodeficiency is acquired later in life due to external factors, such as malnutrition, infection (e.g., human immunodeficiency virus, HIV), or medical therapy (e.g., chemotherapy), which may incapacitate immune functions. In either case, treatment with thymic peptides is beneficial, as it modulates the relevant immune responses to prevent pathological inflammation and further deterioration of the immune system.

A weakened immune system becomes a breeding ground for opportunistic pathogens, leading to chronic or recurrent infections. Unfortunately, conventional antibiotics only target the pathogen to provide temporary relief, which may even compromise immunity by disrupting the gut microbiota. Dr. John H. Knowles (1926-1979), a cardiopulmonary physician who served as the eighth president of the USA Rockefeller Foundation, emphasized that better health and longevity are more likely achieved through healthy living than through medical breakthroughs. In other words, your future health outcomes depend largely on the lifestyle actions you take today rather than what medicine can do for you later.

Our products are formulated to optimize cellular health, as healthy cells lead to overall wellness. This aligns with our four pillars of cellular longevity (Protection, Repair, Revitalization, and Regeneration), which together optimize energy production and health of cells. We are committed to excellence in our therapeutic formulas, choosing each component carefully based on its proven benefits and clinical efficacy, underpinning the science behind our therapies and products.

Biocell Ultravital products are crafted using 100% natural bioactive ingredients, adhering to the highest quality standards. These include cellular extracts from animals, organ and gland extracts from young animals, and peptide hydrolysate extracts from plants, as well as antioxidants, enzymes, and vitamins to enhance the effectiveness and therapeutic range of our formulas.

We meticulously selected raw materials from organic plants and organs of young pigs and sheep under one year of age. These materials undergo rigorous prion inactivation and decontamination pharmaceutical procedures to meet the highest biosecurity standards, ensuring high purity. Our manufacturing processes are strictly controlled to guarantee the unparalleled quality and purity of our products.

Our extraction process does not involve any unwanted or harmful chemicals, using modern technology to maintain the biological integrity and safety of our ingredients. None of the components in our formulas contain genetically modified organisms (GMOs). Each Biocell Ultravital product undergoes an average of five to seven years of rigorous research and development from formulization to market. As a result, only a fraction of investigated formulas (i.e., about 1 in 15) meet our strict criteria for efficacy and become viable options for enhancing cellular health and immune function as either adjunctive or preventive treatments.

Formulated with opotherapeutic (animal organ) extracts and xenogeneic (cross-species) cells, our Cellular Renovation Therapy products focus on strengthening the immune system and supporting primary treatments for diseases linked to immune dysfunction. This achievement stems from the ongoing work of a scientific committee across various institutions working in cellular biology. Consequently, our formulations and products have evolved, aligning with Biocell Ultravital's 4th Generation goals: Protection, Repair, Revitalization, and Regeneration.

The bioactive peptides of Biocell Ultravital's 4th generation products are crafted using a combinational approach of enzymatic hydrolysis with proteolytic enzymes and fermentation with starter cultures. This approach not only ensures the peptides' safe biological activity by removing contaminants and improving intestinal absorption but also reduces allergens. The process involves adding specific enzymes like papain, pepsin, and trypsin to a solution with the targeted gland or organ, which subsequently undergoes incubation to achieve the desired hydrolysis level.

Next, the hydrolysates are fractionated via exclusion and semi-preparative liquid chromatography to isolate the most active peptides, identified via initial in vitro tests. Mass spectrometry and N-terminal sequencing finalize the therapeutic peptide sequence. However, hydrolysates are complex and contain hundreds of different molecules, complicating the identification of bioactive peptides. This requires additional cycles of fractionation and bioactivity evaluation to pinpoint the molecule responsible for the desired effects of each product per its therapeutic indications.

Enzymatic hydrolysis offers notable benefits, especially in preventing degradation of the substrates. As this method leverages the selectivity of enzymes for specific bonds, only targeted reactions can occur, and this precision preserves the substrates' integrity. The enzyme's specificity influences the sequence, size, quantity, and composition of peptides and amino acids, which are important for the production of bioactive peptides. Furthermore, operating within pH ranges of 5-10 and temperatures of 40-60°C helps maintain and enhance the nutritional value of proteins and peptides.

For years, the University Hospitals of Geneva (HUG) has been preparing to conduct cell transplantation using porcine (pig) cells to treat diabetes and liver diseases. This advancement is the fruit of two decades of research, primarily led by two eminent surgeons at the HUG, Professors Dr. Leo Bühler and Dr. Philippe Morel. At present, they await final approvals to breed pigs in Switzerland for this purpose. This innovative approach aims to help patients with diabetes that is unresponsive to traditional insulin treatments, which affects thousands of people in Switzerland.

In diabetes, the pancreas fails to produce sufficient insulin to regulate blood sugar, which can cause serious health issues if not managed properly. “In these patients, the instability of the disease damages all organs,” Dr. Morel, head of the department of vascular surgery at the HUG, said. “This causes the progressive deterioration of blood vessels, which can cause kidney failure, cardiovascular or brain damage. It can even lead to the amputation of a leg.” To avoid severe diabetes complications, pancreas transplantation is sometimes conducted. The HUG conducts about a dozen such transplants yearly, but the feasibility of this procedure is constrained by donor scarcity and a high risk of complications.

Islets of Langerhans (Human pancreatic islets)

Another option to treat diabetes is the transplant of Islets of Langerhans, a group of cells that secrete insulin in the pancreas. This technique was first explored in the 1980s in the USA but initially fell short of expectations. According to Dr. Bühler, “One in five patients stopped being insulin dependent after transplantation, but only temporarily.” However, in 1992, the HUG developed a laboratory center capable of performing successful pancreatic islet transplantations. “More than 200 people have been transplanted at this center, which is one of the largest in the world,” Dr. Morel stated. This success is partly due to advances in immunosuppressive drugs that prevent transplant rejection. While about 80% of patients no longer need insulin injections post-transplant, the rate of maintaining insulin independence drops to 50% of patients at five years later. Nevertheless, the transplanted cells continue to produce some insulin, preventing episodes of hypoglycemia and mitigating disease severity.

The virtues of the pig

The vast gap between the limited number of human donors (one hundred per year) and the high demand for cell transplants (thousands per year) necessitates an alternative solution. Therefore, scientists have attempted transplantation with porcine (pig) pancreatic islet cells instead of human donors’ cells. Pigs are chosen for several reasons, notably because porcine insulin is remarkably similar to human insulin and has been successfully used to treat diabetes since the 1920s.

Moreover, pigs offer a nearly inexhaustible supply of cells for transplantation. The Massachusetts General Hospital in Boston has provided the HUG with six pairs of germ-free pigs, currently housed in Brussels. Professor Dr. Bühler, with five years of xenotransplantation (xeno- means cross-species) training at this hospital, and the HUG collaborated with the École Polytechnique Fédérale de Lausanne (EPFL) team to encapsulate porcine pancreatic islets with biocompatible polymers to prevent them from being rejected by the recipient’s immune system. The biocompatible polymers, Dr. Bühler explained, allow essential molecules like insulin, oxygen, and nutrients to pass through while preventing direct cellular contact.

However, this technique is not perfect as the body may still react to the polymers, forming scar tissue and leading to cell asphyxiation (oxygen-deprived) over time. That said, collaboration with the EPFL has led to the development of more biocompatible polymers, Dr. Bühler noted, which have shown encouraging results in small animal tests, representing a significant step forward.

Overall, Dr. Morel underscores the extensive expertise and resources of the HUG team, particularly in pancreatic islet grafting, xenotransplantation, encapsulating porcine cells, and access to pathogen-free pigs. “In addition, the Swiss law on transplants authorizes this type of transplantation from pig donors,” Dr. Morel said. What about the religious perspectives of Jews and Muslims? Such discussion arose in the 1980s when surgeons implanted porcine heart valves. The Jewish and Islamic religions only forbid the oral intake of pork but did not oppose xenotransplantation from pigs for essential medical purposes.

Healing the Liver Porcine

Porcine cells also offer a potential treatment for acute liver failure, a condition that claims thousands of lives every year due to the lack of timely transplants. Even if the xenotransplantation of porcine liver cells only works temporarily, Dr. Bühler noted that this procedure could buy time until the patient's liver can regenerate. The liver is a special organ that has the capacity to regenerate even if only 10% of it remains. For over two years, the HUG team has been coordinating with Swissmedic, the Swiss Agency for Therapeutic Products, to launch the first clinical trials to explore the therapeutic potential of xenotransplantation of porcine liver cells.

Plans are underway to expand the Arare farm, which is already being used to breed research animals, to further accommodate American pigs in addition to French pigs under sterile conditions. The health state councilor, Mauro Poggia, attended a meeting regarding this expansion on February 24, 2016, in Geneva, highlighting the project's importance and collaborative efforts.

Reference of published article: Le porc, avenir de l’homme (The pig, the future of man) Médecine – La xénotransplantation Tribune de Genève Suisse par Sophie Davaris (Scientific information published in the Tribune newspaper in Geneva Switzerland on Nov 15 / 2015)

Scientific bibliographies.

In 1980 Jean Dausset was awarded the Nobel Prize in Medicine for demonstrating that genetically determined cell surface structures regulate immunological reactions, inspiring in this scientific contribution Wagman decided to incorporate immunological extracts into the formulas of all first-generation Biocell Ultravital products in order to strengthen the immune system.

In 1999, Günter Blobel won the Nobel Prize in Medicine for his work in the 1970s, discovering that proteins have intrinsic signals that govern their transport and location in the cell.

In 2001 Paul Maxime Nurse was the winner of the Nobel Prize in Physiology or Medicine for his discoveries of key regulators of the cell cycle.

In 2007 Martin John Evans was awarded the Nobel Prize in Medicine for his work on stem cells and genetic manipulation in animal models.

In 2016 Yoshinori Ōsumi received the Nobel Prize in Medicine” for his discoveries on the mechanisms of autophagy for survival of mitochondrial energy in cells.